Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST: Immediate Biktarvy Initiation in HIV
NCT03858478Phase 4Unknown
- Start
- Nov 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV). Primary endpoint: Proportion of participants with plasma HIV-RNA < 50 copies/ml at Month 6. Status: unknown.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03858478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03858478.